{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:03:17Z","timestamp":1762506197439,"version":"3.37.3"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1124\/dmd.113.054296","type":"journal-article","created":{"date-parts":[[2013,10,29]],"date-time":"2013-10-29T02:59:45Z","timestamp":1383015585000},"page":"33-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Selective Inhibition of Cytochrome P450 2D6 by Sarpogrelate and Its Active Metabolite, M-1, in Human Liver Microsomes"],"prefix":"10.1016","volume":"42","author":[{"given":"Doo-Yeoun","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Hyeon","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joeng Kee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bom-Taeck","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Kyung","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.113.054296_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cbi.2013.06.006","article-title":"Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes","volume":"205","author":"Bae","year":"2013","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.113.054296_bib2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1634\/theoncologist.11-2-126","article-title":"Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications","volume":"11","author":"Bernard","year":"2006","journal-title":"Oncologist"},{"key":"10.1124\/dmd.113.054296_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0006-2952(85)90101-7","article-title":"Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1\u2032-hydroxylase activities","volume":"34","author":"Boobis","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.113.054296_bib4","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1176\/ajp.153.6.820","article-title":"Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors","volume":"153","author":"Centorrino","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1124\/dmd.113.054296_bib5","series-title":"Drug-Drug Interactions","first-page":"55","article-title":"Human cytochromes P450 and their role in metabolism-based drug-drug interactions","author":"Clarke","year":"2002"},{"key":"10.1124\/dmd.113.054296_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/dmd.31.1.53","article-title":"The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin","volume":"31","author":"Clarke","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.054296_bib7","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1517\/13543784.13.7.865","article-title":"Sarpogrelate: cardiovascular and renal clinical potential","volume":"13","author":"Doggrell","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/dmd.113.054296_bib8","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1067\/mhj.2003.176","article-title":"Sarpogrelate treatment reduces restenosis after coronary stenting","volume":"145","author":"Fujita","year":"2003","journal-title":"Am Heart J"},{"key":"10.1124\/dmd.113.054296_bib9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1055\/s-0038-1646443","article-title":"Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models","volume":"66","author":"Hara","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1124\/dmd.113.054296_bib10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1055\/s-0038-1648163","article-title":"MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist","volume":"65","author":"Hara","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1124\/dmd.113.054296_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0163-7258(99)00048-0","article-title":"Pharmacokinetics of selective serotonin reuptake inhibitors","volume":"85","author":"Hiemke","year":"2000","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.113.054296_bib12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00008571-200110000-00002","article-title":"Unravelling the functional genomics of the human CYP2D6 gene locus","volume":"11","author":"Ingelman-Sundberg","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.113.054296_bib13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2125.2003.02041.x","article-title":"Database analyses for the prediction of in vivo drug-drug interactions from in vitro data","volume":"57","author":"Ito","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.054296_bib14","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1124\/dmd.113.051862","article-title":"Glucuronidation of a sarpogrelate active metabolite is mediated by UDP-glucuronosyltransferases 1A4, 1A9, and 2B4","volume":"41","author":"Kim","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.054296_bib15","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1002\/rcm.2110","article-title":"High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography\/tandem mass spectrometry","volume":"19","author":"Kim","year":"2005","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1124\/dmd.113.054296_bib16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5414\/CP201777","article-title":"Comparison of pharmacokinetics between sarpogrelate hydrochloride immediate-release formulation and controlled-release formulation","volume":"51","author":"Kim","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.054296_bib17","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1067\/mhj.2002.124056","article-title":"Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with angina pectoris","volume":"144","author":"Kinugawa","year":"2002","journal-title":"Am Heart J"},{"key":"10.1124\/dmd.113.054296_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0003-2697(87)90006-6","article-title":"High-performance liquid chromatographic assays for bufuralol 1\u2032-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver","volume":"162","author":"Kronbach","year":"1987","journal-title":"Anal Biochem"},{"key":"10.1124\/dmd.113.054296_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/157488406775268183","article-title":"Pharmacokinetics and metabolic drug interactions","volume":"1","author":"Leucuta","year":"2006","journal-title":"Curr Clin Pharmacol"},{"key":"10.1124\/dmd.113.054296_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2004.08.005","article-title":"Functions of 5-HT2A receptor and its antagonists in the cardiovascular system","volume":"104","author":"Nagatomo","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.113.054296_bib21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00001721-199912000-00009","article-title":"Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin","volume":"10","author":"Nakamura","year":"1999","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1124\/dmd.113.054296_bib22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.054296_bib23","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.105.093229","article-title":"The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions","volume":"316","author":"Obach","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.054296_bib24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1440-1681.1999.03056.x","article-title":"The 5-HT2 receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients","volume":"26","author":"Ogawa","year":"1999","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1124\/dmd.113.054296_bib25","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0022-3565(25)20010-6","article-title":"Use of quinidine inhibition to define the role of the sparteine\/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes","volume":"247","author":"Otton","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.054296_bib26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.2042-7158.1995.tb05801.x","article-title":"In-vitro pharmacology of sarpogrelate and the enantiomers of its major metabolite: 5-HT2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat tail artery","volume":"47","author":"Pertz","year":"1995","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.113.054296_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0049-3848(93)90154-G","article-title":"The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus","volume":"70","author":"Pietraszek","year":"1993","journal-title":"Thromb Res"},{"key":"10.1124\/dmd.113.054296_bib28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0024-3205(03)00227-3","article-title":"Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling","volume":"73","author":"Rashid","year":"2003","journal-title":"Life Sci"},{"key":"10.1124\/dmd.113.054296_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1527-3466.2004.tb00130.x","article-title":"Therapeutic potentials of sarpogrelate in cardiovascular disease","volume":"22","author":"Saini","year":"2004","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1124\/dmd.113.054296_bib30","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0022-3565(24)35055-4","article-title":"Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate","volume":"290","author":"Sharma","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.054296_bib31","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1161\/STROKEAHA.107.505131","article-title":"Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial","volume":"39","author":"Shinohara","year":"2008","journal-title":"Stroke"},{"key":"10.1124\/dmd.113.054296_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1124\/dmd.111.041210","article-title":"Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition","volume":"40","author":"VandenBrink","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.054296_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00004714-199802000-00002","article-title":"Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study","volume":"18","author":"Wetzel","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/dmd.113.054296_bib34","first-page":"209","article-title":"Cytochrome P450 CYP2D6","volume":"148","author":"Wolf","year":"1999","journal-title":"IARC Sci Publ"},{"key":"10.1124\/dmd.113.054296_bib35","first-page":"321","article-title":"Conjunctive effects of the 5HT(2) receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in different laser-induced thrombosis models","volume":"30","author":"Yamashita","year":"2000","journal-title":"Haemostasis"},{"key":"10.1124\/dmd.113.054296_bib36","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/jps.10179","article-title":"Inhibition-based metabolic drug-drug interactions: predictions from in vitro data","volume":"91","author":"Yao","year":"2002","journal-title":"J Pharm Sci"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624098064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624098064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.113.054296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:11:21Z","timestamp":1739905881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624098064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0090955624098064"],"URL":"https:\/\/doi.org\/10.1124\/dmd.113.054296","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective Inhibition of Cytochrome P450 2D6 by Sarpogrelate and Its Active Metabolite, M-1, in Human Liver Microsomes","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.113.054296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}